Welcome to our dedicated page for Embecta news (Ticker: EMBC), a resource for investors and traders seeking the latest updates and insights on Embecta stock.
Embecta Corp. (EMBC) generates a steady stream of news as a global diabetes care and medical supplies company listed on The Nasdaq Global Select Market. The company describes itself as advancing a 100-year legacy in insulin delivery and working to transform from an insulin delivery company into a broader medical supplies company. News about embecta often reflects this strategic evolution and its role in diabetes care worldwide.
Investors and observers can expect frequent updates tied to financial performance, including quarterly and full-year earnings results. embecta regularly issues press releases detailing revenues by geography and product family, operating margins, adjusted metrics, and guidance for upcoming fiscal years. These announcements are often accompanied by commentary on business drivers such as product volumes, pricing, foreign currency effects, and contract manufacturing activity.
Another key category of news covers strategic initiatives and partnerships. embecta has highlighted its global ERP implementation, brand transition from BD-branded to embecta-branded injection devices, and restructuring efforts aimed at improving profitability and reducing debt. The company also reports on collaborations with pharmaceutical partners to co-package embecta pen needles with potential generic GLP-1 therapies, as well as humanitarian partnerships, including large-scale donations of pen needles and insulin syringes through organizations such as Direct Relief.
embecta’s news flow also includes corporate governance and capital allocation topics, such as board changes, upcoming investor conferences, and regular announcements of quarterly cash dividends. Together, these updates provide insight into how embecta manages its diabetes-focused portfolio, pursues growth opportunities, and communicates with stockholders. For readers tracking EMBC, this news page offers an organized view of the company’s financial disclosures, strategic milestones, and corporate developments over time.
embecta (Nasdaq: EMBC) agreed to acquire UK-based Owen Mumford for up to £150 million—£100 million upfront plus up to £50 million in performance payments tied to Aidaptus® sales over three years. The deal is expected to close in embecta’s fiscal Q3 2026, subject to approvals.
The acquisition adds drug-delivery platforms, a £69.4M FY2025 revenue base, manufacturing capabilities and global commercial reach to accelerate embecta’s transformation into a broad-based medical supplies company.
embecta (Nasdaq: EMBC) announced board leadership changes effective February 11, 2026: Devdatt "Dev" Kurdikar was elected Chairman of the Board and Dr. Claire Pomeroy was elected Lead Independent Director. These changes follow the retirement of LTG (Ret.) David F. Melcher.
Kurdikar joins as chairman after serving as president and CEO of a diabetes care spinoff since 2022. Dr. Pomeroy will continue to chair the Corporate Governance and Nominating Committee and serve on the Technology, Quality and Regulatory Committee.
Embecta (Nasdaq: EMBC) reported first quarter fiscal 2026 financial results on February 5, 2026. The company directs investors to its Investor Relations website for the detailed earnings release and presentation.
Embecta hosted a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET on February 5, 2026, with a replay available beginning at 11:00 a.m. ET on February 5, 2026 and archived for one year on the investor relations site.
embecta (Nasdaq: EMBC) declared a quarterly cash dividend of $0.15 per share. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026. This applies to all issued and outstanding common shares.
embecta (Nasdaq: EMBC) will report fiscal first quarter 2026 results and host a conference call on Thursday, February 5, 2026 at 8:00 a.m. ET. The call will include an operational update and a Q&A session. Investors can access a live webcast or teleconference, and a webcast replay will be available beginning at 11:00 a.m. ET on February 5, 2026 and archived on the embecta investor relations website for one year.
Embecta (Nasdaq: EMBC) said management will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 2:15 p.m. PT / 5:15 p.m. ET. Audio webcasts of the presentations will be available in the News & Events section of the company's investor relations website at investors.embecta.com.
embecta (Nasdaq: EMBC) reported fourth-quarter FY2025 and full-year results for periods ended September 30, 2025.
Key Q4 metrics: revenues $264.0M (down 7.7% YoY), adjusted EBITDA margin 34.1%, GAAP diluted EPS $0.45, adjusted diluted EPS $0.50, and a declared quarterly dividend of $0.15 per share. Full-year results: revenues $1,080.4M (down 3.8% YoY), adjusted EBITDA margin 38.5%, adjusted diluted EPS $2.95, and free cash flow ~$182M.
Operational notes: management cited distributor ordering timing and China dynamics for revenue pressure, completed major separation activities, reduced debt by ~$184.5M in FY2025, and provided preliminary FY2026 guidance: revenues $1,071–$1,093M, adjusted operating margin 29.0%–30.0%, adjusted EPS $2.80–$3.00.
embecta (Nasdaq: EMBC) declared a quarterly cash dividend of $0.15 per share.
The dividend is payable on December 18, 2025 to stockholders of record at the close of business on December 5, 2025.
embecta (Nasdaq: EMBC) announced board changes on November 17, 2025. Director David J. Albritton resigned effective immediately for personal reasons, and Non-Executive Chairman LTG (Ret.) David F. Melcher will not stand for re-election and will retire at embecta’s 2026 annual stockholder meeting. Both directors served on the Board since its 2022 inception.
The Board expects to appoint Devdatt “Dev” Kurdikar as Chairman and Dr. Claire Pomeroy as Lead Independent Director effective upon Melcher’s departure. The Corporate Governance and Nominating Committee will evaluate desired independent director expertise and recommend potential replacements.
embecta (Nasdaq: EMBC) announced on Nov 14, 2025 a major expansion of its humanitarian partnership with Direct Relief to increase global and U.S. access to diabetes injection devices. Following a North America packaging transition, embecta donated approximately 15 million pen needles and insulin syringes and will continue support through 2026.
The commitment funds emergency response, supports more than 1,600 community health centers serving ~36 million patients, aids the Life for a Child program (53,000+ children in 45 countries), and included a recent 2.7 million unit donation for Sudan; embecta also provided a July 2025 grant of $25,000 for Texas storm relief.